Oct 24, 2016
Are cancer drugs worth the cost? That’s the question a controversial Boston-based non-profit, the Institute for Clinical and Economic Review (ICER), convened about last week in St. Louis to discuss. The group, who notoriously “cherry-picks data,” often reviews new...
Oct 19, 2016
Having just hosted the latest of a decades-long string of presidential debates, St. Louis is rightfully proud of serving as a setting for vital national conversations. On Oct. 20, the Gateway City will be the site of another gathering that could also prove...
Oct 17, 2016
Ahead of an ICER meeting to review evidence and vote on cost-effectiveness ratings for non-small cell lung cancer treatments, a group of oncologists is airing “serious concerns” about the organization’s assessment techniques. The docs have laid out principles that...
Sep 29, 2016
Patients Rising is a Washington, DC-based non-profit organization with a very specific mission: we advocate for access to vital therapies and services for all patients with life-threatening and chronic diseases. That is why Patients Rising is committed to bringing...
Jun 25, 2016
After concluding that because myeloma drugs keep people alive longer they cost too much to be cost-effective, ICER through it’s Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) is now looking at new drugs for treating people with non small...
